On Wednesday, Xencor received a positive adjustment to its Relative Strength (RS) Rating, from 78 to 81.
IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners tend to have an 80 or higher RS Rating in the early stages of their moves.
Risk Management In The Stock Market: How Much Money To Invest Now
Xencor is within a buying range after moving past a 25.41 buy point in a consolidation. The proper buying range is up to 5% above the initial entry. Once a stock moves above that range, it's best to wait for it to set up another buying opportunity.
Xencor reported 0% EPS growth last quarter, while sales growth came in at -82%.
Xencor holds the No. 188 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
